Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.37 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.36 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.36 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.35 |
| ▸ | MAOB | P27338 | 3/20 | 0.35 |
| ▸ | MAPT | P10636 | 3/20 | 0.34 |
| ▸ | NPC1 | O15118 | 2/20 | 0.34 |
| ▸ | RAB9A | P51151 | 2/20 | 0.34 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | PDE5A | O76074 | 1/20 | 0.33 |
| ▸ | CRHBP | P24387 | 1/20 | 0.33 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.33 |
| ▸ | CES2 | O00748 | 2/20 | 0.32 |
| ▸ | CES1 | P23141 | 2/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4426787 | 0.73 | ALDH1A1 (0.39) | ALDH1A1SMN1; SMN2LMNASRD5A2NPC1 | |
| SCHEMBL232142 | 0.69 | UNG (0.45) | ALDH1A1MAOBNPC1FFAR1MEN1 | |
| SCHEMBL5391673 | 0.68 | CA12 (0.37) | ALDH1A1SMN1; SMN2KDM4EMEN1KMT2A | |
| SCHEMBL439235 | 0.64 | ACHE (0.42) | ALDH1A1SMN1; SMN2LMNAMAPTRAB9A | |
| SCHEMBL29926357 | 0.63 | ACHE (0.47) | ALDH1A1SMN1; SMN2LMNAMAPTNPSR1 | |
| P-Xylene SCHEMBL14721484 | 0.62 | ALDH1A1 (0.67) | ALDH1A1SMN1; SMN2LMNASRD5A2MAPT | |
| P-Xylene SCHEMBL27538150 | 0.62 | ALDH1A1 (0.67) | ALDH1A1SMN1; SMN2LMNASRD5A2MAPT | |
| 4-Methylbenzoic Acid SCHEMBL28174639 | 0.61 | ALDH1A1 (0.94) | ALDH1A1SMN1; SMN2LMNASRD5A2CES2 | |
| SCHEMBL17818420 | 0.61 | RAB9A (0.39) | ALDH1A1SMN1; SMN2LMNAMAPTNPC1 | |
| SCHEMBL12510550 | 0.60 | ACHE (0.42) | ALDH1A1SMN1; SMN2LMNAMAPTNPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2455375-B1 | Diacylhydrazine ligands for modulating the expression of exogenous genes in mammalian systems via an ecdysone receptor complex | INTREXON CORP (US) | 2014-11-19 | — | — | EP | disclosed |
| US-8748125-B2 | Diacylhydrazine ligands for modulating the expression of exogenous genes in mammalian systems via an ecdysone receptor complex | INTREXON CORPORATION (US) | 2014-06-10 | — | — | US | disclosed |
| EP-2455375-A2 | Diacylhydrazine ligands for modulating the expression of exogenous genes in mammalian systems via an ecdysone receptor complex | Intrexon Corporation (US) | 2012-05-23 | — | — | EP | disclosed |
| US-7851220-B2 | Reduced level of background gene expression; responds to submicromolar concentrations of nonsteroidal ligand | INTREXON CORPORATION (US) | 2010-12-14 | — | — | US | disclosed |
| US-20080214627-A1 | 3,5-Dimethyl-benzoic acid N-tert-butyl-N'-(3-hydroxymethyl-5-methyl-2,3-dihydro-benzo[1,4]dioxine-6-carbonyl)-hydrazide; side effect reduction; genetic engineering | HORMANN ROBERT EUGENE | 2008-09-04 | — | — | US | disclosed |
| US-20080194521-A1 | 3,5-Dimethyl-benzoic acid N-tert-butyl-N'-(3-hydroxymethyl-5-methyl-2,3-dihydro-benzo[1,4]dioxine-6-carbonyl)-hydrazide; side effect reduction; genetic engineering | HORMANN ROBERT EUGENE | 2008-08-14 | — | — | US | disclosed |
| EP-1603860-A4 | DIACYLHYDRAZINE LIGANDS FOR MODULATING THE EXPRESSION OF EXOGENOUS GENES IN MAMMALIAN SYSTEMS VIA AN ECDYSONE RECEPTOR COMPLEX | INTREXON CORP (US) | 2008-05-14 | — | — | EP | disclosed |
| US-20080103113-A1 | Reduced level of background gene expression; responds to submicromolar concentrations of nonsteroidal ligand | HORMANN ROBERT E | 2008-05-01 | — | — | US | disclosed |
| US-7304161-B2 | 3,5-Dimethyl-benzoic acid N-tert-butyl-N'-(3-hydroxymethyl-5-methyl-2,3-dihydro-benzo[1,4]dioxine-6-carbonyl)-hydrazide; 3,5-Dimethyl-benzoic acid N-(1-tert-butyl-2-cyano-vinyl)-N'-(3-methoxy-2-methylbenzoyl)-hydrazide | INTREXON CORPORATION (US) | 2007-12-04 | — | — | US | disclosed |
| US-20070123574-A1 | Methods for the preparation of benzoxazole sulfonamide compounds and intermediates thereof | DE KOCK HERMAN A | 2007-05-31 | — | — | US | disclosed |
| EP-1670773-B1 | METHODS FOR THE PREPARATION OF BENZOXAZOLE SULFONAMIDE COMPOUNDS AND INTERMEDIATES THEREOF | TIBOTEC PHARM LTD (IE) | 2007-02-07 | — | — | EP | disclosed |
| EP-1670773-A1 | METHODS FOR THE PREPARATION OF BENZOXAZOLE SULFONAMIDE COMPOUNDS AND INTERMEDIATES THEREOF | Tibotec Pharmaceuticals Ltd. (IE) | 2006-06-21 | — | — | EP | disclosed |
| EP-1603860-A2 | DIACYLHYDRAZINE LIGANDS FOR MODULATING THE EXPRESSION OF EXOGENOUS GENES IN MAMMALIAN SYSTEMS VIA AN ECDYSONE RECEPTOR COMPLEX | RheoGene Holdings Inc. (US) | 2005-12-14 | — | — | EP | disclosed |
| US-20050209283-A1 | 3,5-Dimethyl-benzoic acid N-tert-butyl-N'-(3-hydroxymethyl-5-methyl-2,3-dihydro-benzo[1,4]dioxine-6-carbonyl)-hydrazide; 3,5-Dimethyl-benzoic acid N-(1-tert-butyl-2-cyano-vinyl)-N'-(3-methoxy-2-methylbenzoyl)-hydrazide | ROHM AND HAAS COMPANY | 2005-09-22 | — | — | US | disclosed |
| WO-2005030739-A1 | METHODS FOR THE PREPARATION OF BENZOXAZOLE SULFONAMIDE COMPOUNDS AND INTERMEDIATES THEREOF | TIBOTEC PHARMACEUTICALS LTD. (IE) | 2005-04-07 | — | — | WO | disclosed |
| WO-2004072254-A2 | DIACYLHYDRAZINE LIGANDS FOR MODULATING THE EXPRESSION OF EXOGENOUS GENES IN MAMMALIAN SYSTEMS VIA AN ECDYSONE RECEPTOR COMPLEX | RHEOGENE HOLDINGS, INC (US) | 2004-08-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080214627-A1 | 3,5-Dimethyl-benzoic acid N-tert-butyl-N'-(3-hydroxymethyl-5-methyl-2,3-dihydro-benzo[1,4]dioxine-6-carbonyl)-hydrazide; side effect reduction; genetic engineering | NR5A2, NR5A1, DECR1 | ALDH1A1 1447/4885SMN1; SMN2 4490/4885LMNA 2390/4885 |
| US-20070123574-A1 | Methods for the preparation of benzoxazole sulfonamide compounds and intermediates thereof | STS, MPST, SULT1E1 | ALDH1A1 858/4885SMN1; SMN2 2570/4885LMNA 3074/4885 |
| US-20080194521-A1 | 3,5-Dimethyl-benzoic acid N-tert-butyl-N'-(3-hydroxymethyl-5-methyl-2,3-dihydro-benzo[1,4]dioxine-6-carbonyl)-hydrazide; side effect reduction; genetic engineering | NR5A2, NR5A1, DECR1 | ALDH1A1 1447/4885SMN1; SMN2 4490/4885LMNA 2390/4885 |
| US-20080103113-A1 | Reduced level of background gene expression; responds to submicromolar concentrations of nonsteroidal ligand | NR5A1, NR0B2, NR0B1 | ALDH1A1 4095/4885SMN1; SMN2 4661/4885LMNA 2772/4885 |
| US-20050209283-A1 | 3,5-Dimethyl-benzoic acid N-tert-butyl-N'-(3-hydroxymethyl-5-methyl-2,3-dihydro-benzo[1,4]dioxine-6-carbonyl)-hydrazide; 3,5-Dimethyl-benzoic acid N-(1-tert-butyl-2-cyano-vinyl)-N'-(3-methoxy-2-methylbenzoyl)-hydrazide | NR5A2, NR2C2, NR0B2 | ALDH1A1 2130/4885SMN1; SMN2 4646/4885LMNA 1762/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.